NTT-LTD.
4.11.2021 10:02:19 CET | Business Wire | Press release
NTT Ltd. , a global technology and business solutions provider, is today announcing a series of commitments to reduce its carbon footprint and create a connected future that is both more sustainable and inclusive for all. NTT will work to achieve net zero emissions across its operations by 2030 and its value chain by 2040. It is also driving towards powering its Global Data Center Division - an operation of almost 600,000m2 across 20 countries and regions – with 100% renewable energy by 2030 as an urgent priority.
Additionally, NTT is proud to have joined the United Nation’s Race to Zero campaign. This follows the company joining the Business Ambition Pledge for 1.5°C and committing to the Science Based Targets initiative (SBTi). These initiatives are regarded as the gold standard for corporate climate action. They aim to support businesses who are committing to ambitious targets to limit global warming to 1.5°C and avoid the worst effects of climate change.
NTT Ltd.’s Global Chief Executive Officer, Abhijit Dubey, commented, “As one of the largest technology companies in the world, we have an obligation to make the world a more sustainable place. Employees, customers and partners are demanding that companies become more purpose-led. This is core to our NTT heritage, and I am incredibly proud to be announcing our commitment to reach net zero emissions and broader strategic sustainability goals. This is a significant step for us, which will see NTT using technology not only to help the world become more sustainable, but also to be connected long into the future. We will continue making investments in technology, people and programs to achieve these goals.”
NTT’s strategic framework is focused on accelerating sustainable and transformational change across three interconnected pillars:
-
Connected Planet:
- Develop new and expand on existing partnerships to scale technology solutions focused on the protection and regeneration of biodiversity and ecosystems on every continent it operates in support of a more positive future by 2025
- Incorporate circular economy and regenerative design principles working in partnership across its operations, supply chain and client solutions by 2026
- Engage 50% of its employees in conservation and regenerative initiatives in their local communities in support of the UN SDGs and the UN Decade on Ecosystem Restoration by 2025
-
Connected Economy:
- Grow its portfolio of smart solutions to support its clients and partners in decreasing 200m tonnes of greenhouse gas (GHG) emissions by 2026
- Establish a Sustainability Innovation Fund, review board and mentorship program to incubate ideas and scale the impact of climate tech and sustainable solutions and in support of the UN SDGs
-
Connected Communities:
- Ensure that more than 50% of its workforce will belong to one or more of the diversity categories of gender, race, sexual orientation, socio-economic background and disability. To further reinforce this commitment, NTT will double the diversity of its executive leadership team with an emphasis on female representation by 2025
- Provide 5 million young people and children from underprivileged areas across the world with digital access and education to reduce inequality and build critical skills and opportunities for a connected future by 2030
- Enable and empower its employees to contribute 1 million hours of volunteering to support the initiatives forming the three interconnected pillars and in support of the UN SDGs by 2025
Commenting on the NTT’s sustainability commitments, Marilyn Chaplin, Chief Human Resources and Sustainability Officer at NTT Ltd., said, “We know that the greatest opportunity to make a positive impact is through our people, operations, and our core business solutions. This strategic framework gives us clear direction towards making a tangible difference across societies, the economy and our planet. It also provides us with an opportunity to further support our existing initiatives, such as the Connected Conservation Foundation , which uses technology to reduce poaching, and ROBOCEAN , a start-up looking to reduce climate change through the conservation of seagrass. I look forward to working with our talented and diverse ecosystem of stakeholders to help accelerate the change we need to see in the world and making these commitments a reality.”
Visit our website to learn more about our commitment to making the world a more sustainable place.
NTT Ltd. is part of NTT Group, which is committing to zero emissions across its entire group and subsidiaries by 2040.
ENDS
About NTT
NTT Ltd. is a leading global technology services company. Working with organizations around the world, we achieve business outcomes through intelligent technology solutions. For us, intelligent means data driven, connected, digital and secure. Our global assets and integrated ICT stack capabilities provide unique offerings in cloud-enabling networking, hybrid cloud, data centers, digital transformation, client experience, workplace, and cybersecurity. As a global ICT provider, we employ more than 40,000 people in a diverse and dynamic workplace that spans 57 countries, trading in 73 countries and delivering services in over 200 countries and regions. Together we enable the connected future.
Visit us at hello.global.ntt
About Business Ambition for 1.5°C:
Business Ambition for 1.5°C is a campaign led by the Science Based Targets initiative in partnership with the UN Global Compact and the We Mean Business Coalition. It was launched in 2019 by a global coalition of UN agencies, business and industry leaders.
About Race to Zero:
Race to Zero is the UN-backed global campaign rallying non-state actors – including companies, cities, regions, financial and educational institutions – to take rigorous and immediate action to halve global emissions by 2030 and deliver a healthier, fairer zero carbon world in time. Led by the High-Level Champions for Climate Action – Nigel Topping and Gonzalo Muñoz – Race to Zero mobilizes actors outside of national governments to join the Climate Ambition Alliance, which was launched at the UNSG’s Climate Action Summit 2019 by the President of Chile, Sebastián Piñera.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211104005516/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
